1:53 PM
Jan 09, 2019
 |  BC Extra  |  Clinical News

Patient receives glioblastoma vaccine under right to try

ERC-USA and the University of California Irvine announced that a patient with recurrent glioblastoma multiforme is receiving therapeutic vaccine ERC1671 under California's right-to-try (RTT) law.

ERC1671 is in a U.S. Phase II trial as part of a once-monthly combination treatment for recurrent GBM and gliosarcoma. The patient, who did not qualify for enrollment in that trial, began receiving ERC1671 in November under RTT. ERC-USA did not respond in time for publication to inquiries regarding why the patient applied for RTT instead of using FDA's expanded access program.

ERC1671, known as Gliovac in Europe, combines autologous tumor cells with allogeneic tumor cells derived from three donor patients with cancer, plus lysates of all of those cells.

ERC-USA is a subsidiary of ERC-Belgium S.A. (Les Isnes, Belgium).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD